Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters

Nuclear Medicine and Biology

Volumn 34, Issue 3, 2007, Pages 239-246

  Kung, Mei Ping ^a   Hou, Catherine ^a   Goswami, Rajesh ^a   Ponde, Datta E ^a   Kilbourn, Michael R ^b   Kung, Hank F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

9 Fluoropropyl dihydrotetrabenazine; PET imaging agent; Vesicular monoamine transporters

Indexed keywords

9 FLUOROPROPYL 9 O NORDIHYDROTETRABENAZINE; 9 FLUOROPROPYL DIHYDROTETRABENAZINE; DOPAMINE TRANSPORTER; N (3' IODOPROPEN 2' YL) 2 BETA CARBOMETHOXY 3 BETA (4 CHLOROPHENYL)TROPANE I 125; OXIDOPAMINE; TRACER; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN REGION; BRAIN TISSUE; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; DRUG DISTRIBUTION; DRUG LABELING; DRUG STABILITY; EX VIVO STUDY; EXTRACTION; IN VIVO STUDY; ISOMER; LOCUS CERULEUS; MALE; MONOAMINE NERVE CELL; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY BULB; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; RADIOACTIVITY; SUBSTANTIA NIGRA;

ANIMALS; BRAIN; FEASIBILITY STUDIES; FLUORINE RADIOISOTOPES; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED ICR; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STEREOISOMERISM; TETRABENAZINE; TISSUE DISTRIBUTION; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 33947305764     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.12.005     Document Type: Article

References (30)

1. Albin R., and Koeppe R. Rapid loss of striatal VMAT2 binding associated with onset of Lewy body dementia. Mov Disord 21 (2006) 287-288
2. Kilbourn M.R. In vivo radiotracers for vesicular neurotransmitter transporters. Nucl Med Biol 24 (1997) 615-619
3. Stoessl A.J., and de la Fuente-Fernandez R. Dopamine receptors in Parkinson's disease: imaging studies. Adv Neurol 91 (2003) 65-71
4. Tatsch K. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease?. Eur J Nucl Med Mol Imaging 29 (2002) 711-714
5. Frey K.A. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease?. Eur J Nucl Med Mol Imaging 29 (2002) 715-717
6. Guilloteau D., and Chalon S. PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders. Curr Pharm Des 11 (2005) 3237-3245
7. Ravina B., Eidelberg D., Ahlskog J.E., Albin R.L., Brooks D.J., Carbon M., et al. The role of radiotracer imaging in Parkinson disease. Neurology 64 (2005) 208-215
8. Van Laere K., Casteels C., De Ceuninck L., Vanbilloen B., Maes A., Mortelmans L., et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med 47 (2006) 384-392
9. Booij J., Habraken J.B., Bergmans P., Tissingh G., Winogrodzka A., Wolters E.C., et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 39 (1998) 1879-1884
10. Innis R.B., Seibyl J.P., Scanley B.E., Laruelle M., Abi-Dargham A., Wallace E., et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A 90 (1993) 11965-11969
11. 99mTc]TRODAT-1 as dopamine transporter imaging agents. J Med Chem 41 (1998) 428-436
12. 99mTc]TRODAT-1 to dopamine transporters in patients with parkinson's disease and in healthy volunteers. J Nucl Med 41 (2000) 584-589
13. 3H]Methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 68 (1995) 955-962
14. Kilbourn M., and Frey K. Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains. Eur J Pharmacol 307 (1996) 227-232
15. Kilbourn M.R., Kuszpit K., and Sherman P. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse 35 (2000) 250-255
16. Kilbourn M.R., Frey K.A., Vander Borght T., and Sherman P.S. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol 23 (1996) 467-471
17. Frey K.A., Koeppe R.A., and Kilbourn M.R. Imaging the vesicular monoamine transporter. Adv Neurol 86 (2001) 237-247
18. Bohnen N.I., Albin R.L., Koeppe R.A., Wernette K.A., Kilbourn M.R., Minoshima S., et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 26 (2006) 1198-1212
19. Lee C.S., Schulzer M., de la Fuente-Fernandez R., Mak E., Kuramoto L., Sossi V., et al. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Arch Neurol 61 (2004) 1920-1925
20. Albin R.L., Koeppe R.A., Bohnen N.I., Nichols T.E., Meyer P., Wernette K., et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 61 (2003) 310-315
21. Mehvar R., Jamali F., Watson M.W., and Skelton D. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug Metab Dispos 15 (1987) 250-255
22. Kilbourn M.R., Lee L.C., Heeg M.J., and Jewett D.M. Absolute configuration of (+)-alpha-dihydrotetrabenazine, an active metabolite of tetrabenazine. Chirality 9 (1997) 59-62
23. 3H]dihydrotetrabenazine to the vesicular monoamine transporter of rat brain: bolus vs. equilibrium studies. Eur J Pharmacol 331 (1997) 161-168
24. Frey K.A., Koeppe R.A., Kilbourn M.R., Vander Borght T.M., Albin R.L., Gilman S., et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 40 (1996) 873-884
25. Goswami R., Ponde D.E., Kung M.P., Hou C., Kilbourn M.R., and Kung H.F. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol 33 (2006) 685-694
26. Kung M.-P., Essman W.D., Frederick D., Meegalla S., Goodman M., Mu M., et al. IPT: a novel iodinated ligand for the CNS dopamine transporter. Synapse 20 (1995) 316-324
27. 3H]Dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J Neurochem 50 (1988) 1131-1136
28. Kilbourn M., Lee L., Borght T.V., Jewett D., and Frey K. Binding of [alpha]-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol 278 (1995) 249-252
29. Schwarting R.K.W., and Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50 (1996) 275-331
30. 3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum. Neurosci Lett 114 (1990) 45-50